CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 28 enrolled
Drug / intervention
Gemfibrozil +1 moredrug
Likely dose
Gemfibrozil 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01876810
NCT01876810Phase 2Completed

Testing the PPAR Hypothesis of Nicotine Dependence in Humans: Gemfibrozil as a Novel Treatment for Tobacco Addiction

Centre for Addiction and Mental Health·interventional·Posted Jun 13, 2013·Updated Apr 20, 2017

In Brief

A Phase 2 clinical trial evaluating Gemfibrozil and Placebo for Nicotine Dependence. Completed, enrolled 28 participants across 2 sites.

Detailed Summary

The purpose of this study is to investigate the effect of gemfibrozil on nicotine reinforcement and cue-elicited craving. Other objectives of this study include screening for the ability of gemfibrozil to aid smoking abstinence during a brief quit attempt and examining the validity of using laboratory measures of tobacco dependence to predict smoking abstinence. It is hypothesized that gemfibrozil will result in diminished nicotine reinforcement, an attenuated response to smoking cues, and an increase in smoking abstinence compared with placebo. It is also hypothesized that the laboratory measures will prove valid in predicting abstinence.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJun 13, 2013
Enrollment StartFeb 1, 2014
Primary CompletionFeb 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 13.1 years ago

Interventions

Gemfibrozildrug

600 mg of gemfibrozil (one capsule) twice daily for two weeks.

Placebodrug

One lactose pill twice a day for two weeks.